Dr. Negin Hajizadeh, MD, MPH Internal Medicine - Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 330 Bridge St, Greenport, NY 11944 Phone: 401-935-1027 Fax: 212-562-1759 |
News Archive
Black and Hispanic people with COVID-19 and diabetes are more likely than Caucasians to die or have serious complications, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, today commented on a Special Notice published by the US Department of Health and Human Services (DHHS), Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) on December 29, 2009.
VIVUS, Inc., a biopharmaceutical company developing innovative, next-generation medical therapies to address unmet needs in obesity, diabetes and sexual health, announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of Qnexa, its investigational drug for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.
Dr. Roger Zemek, Director of Emergency Research at the CHEO Research Institute and ED physician, and assistant professor in the Faculty of Medicine at the University of Ottawa, has overseen the creation and implementation of a Medical Directive that now empowers nurses to administer an oral steroid treatment, which has reduced wait time and improved patient care. This research is published today in Pediatrics.
› Verified 2 days ago